Motus GI Holdings Inc (NASDAQ:MOTS) has been given a consensus recommendation of “Buy” by the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $9.63.
Several analysts have issued reports on the company. Zacks Investment Research upgraded Motus GI from a “sell” rating to a “hold” rating in a research note on Tuesday, April 2nd. ValuEngine lowered Motus GI from a “buy” rating to a “hold” rating in a research note on Thursday, May 23rd. Piper Jaffray Companies lowered their target price on Motus GI from $8.00 to $6.00 in a research note on Friday, May 10th. Finally, Oppenheimer set a $10.00 price objective on Motus GI and gave the company a “buy” rating in a research note on Thursday, March 28th.
Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC purchased a new position in Motus GI during the first quarter worth about $43,000. Spark Investment Management LLC grew its position in Motus GI by 73.5% during the first quarter. Spark Investment Management LLC now owns 28,900 shares of the company’s stock worth $112,000 after buying an additional 12,245 shares in the last quarter. IPG Investment Advisors LLC grew its position in Motus GI by 22.7% during the fourth quarter. IPG Investment Advisors LLC now owns 36,500 shares of the company’s stock worth $114,000 after buying an additional 6,750 shares in the last quarter. Maven Securities LTD purchased a new position in Motus GI during the fourth quarter worth about $167,000. Finally, Eaton Vance Management grew its position in Motus GI by 75.0% during the fourth quarter. Eaton Vance Management now owns 70,000 shares of the company’s stock worth $218,000 after buying an additional 30,000 shares in the last quarter. Institutional investors own 35.30% of the company’s stock.
Motus GI (NASDAQ:MOTS) last issued its earnings results on Friday, May 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.29). Sell-side analysts anticipate that Motus GI will post -1.13 earnings per share for the current fiscal year.
Motus GI Company Profile
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
See Also: Balanced Fund
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.